1. Home
  2. KBDC vs ARDX Comparison

KBDC vs ARDX Comparison

Compare KBDC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

SELL

Current Price

$13.00

Market Cap

822.8M

Sector

N/A

ML Signal

SELL

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$3.30

Market Cap

797.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
ARDX
Founded
2021
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
822.8M
797.8M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
KBDC
ARDX
Price
$13.00
$3.30
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
★ $14.50
$12.80
AVG Volume (30 Days)
398.5K
★ 4.7M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
★ 12.31%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.85
N/A
Revenue
N/A
★ $2,607,000.00
Revenue This Year
N/A
$18.42
Revenue Next Year
N/A
$28.82
P/E Ratio
$15.29
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.14
$2.96
52 Week High
$15.87
$8.40

Technical Indicators

Market Signals
Indicator
KBDC
ARDX
Relative Strength Index (RSI) 53.25 38.51
Support Level $12.88 N/A
Resistance Level $13.65 $3.35
Average True Range (ATR) 0.28 0.13
MACD 0.07 0.01
Stochastic Oscillator 76.00 21.37

Price Performance

Historical Comparison
KBDC
ARDX

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: